University of Milano-Bicocca
🇮🇹Italy
Ponatinib Shows Superior Survival Outcomes in Ph+ ALL Patients with Persistent MRD After Induction
Post hoc analysis of the PhALLCON trial demonstrates that ponatinib achieved higher rates of deep molecular responses compared to imatinib in newly diagnosed Ph+ ALL patients who remained MRD-positive after induction therapy.